Vis enkel innførsel

dc.contributor.authorDonders, Gilbert
dc.contributor.authorGrinceviciene, Svitrigaile
dc.contributor.authorHaldre, Kai
dc.contributor.authorLonnee-Hoffmann, Risa
dc.contributor.authorDonders, Francesca
dc.contributor.authorTsiakalos, Aristotelis
dc.contributor.authorAdriaanse, Albert
dc.contributor.authorMartinez de Oliveira, Jose
dc.contributor.authorAult, Kevin A.
dc.contributor.authorMendling, Werner
dc.date.accessioned2023-02-14T14:52:28Z
dc.date.available2023-02-14T14:52:28Z
dc.date.created2021-06-29T14:31:08Z
dc.date.issued2021
dc.identifier.issn2077-0383
dc.identifier.urihttps://hdl.handle.net/11250/3050815
dc.description.abstractIntroduction. Sars-CoV-2 infection poses particular problems in pregnancy, as the infection more frequently causes severe complications than in unaffected pregnant women or nonpregnant women with SARS-CoV-2 infection. Now that vaccination is available and rapidly being implemented worldwide, the question arises whether pregnant women should be vaccinated, and if so, whether they should receive priority. Methods. Available scientific data and available guidelines about vaccination against SARS-CoV-2 were collected by the Guideline Committee of the International Society of Infectious Diseases in Obstetrics and Gynecology (ISIDOG) and were analyzed, discussed and summarized as guidelines for healthcare workers caring for pregnant women. Concluding statements were graded according to the Oxford evidence-based medicine grading system. Results. There is evidence to consider pregnancy as a risk factor for serious complications of COVID-19 infection, even in the absence of additional risk factors, such as hypertension, diabetes and obesity which increase these risks even more in pregnancy. Currently available data slightly favor mRNA-based vaccines above vector-based vaccines during pregnancy and breastfeeding, until more safety data become available. Conclusion. ISIDOG advises policy makers and societies to prioritize pregnant women to receive vaccination against SARS-CoV-2 and favor the mRNA vaccines until further safety information becomes available.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleISIDOG Consensus Guidelines on COVID-19 Vaccination for Women before, during and after Pregnancyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.journalJournal of Clinical Medicineen_US
dc.identifier.doi10.3390/jcm10132902
dc.identifier.cristin1919353
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal